Updated: JAK woes continue as Eli Lilly warns of possible Olumiant CRL for atopic dermatitis and reports PhIII fail in lupus
Eli Lilly and Incyte have plans to turn their blockbuster Olumiant drug into a megablockbuster. But those plans ran into a major roadblock Friday morning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.